New antibiotic combo tested against superbugs in hospitals

NCT ID NCT07176247

ENROLLING_BY_INVITATION Disease control Sponsor: French Society for Intensive Care Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tracks 100 hospital patients with hard-to-treat bacterial infections who receive the antibiotic combination aztreonam-avibactam. Researchers will measure how often the infection clears up without needing more antibiotics. The goal is to see how well this drug works in real-world settings, outside of strict clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Aztreonam-avibactam (antibiotic combination)
What this could lead to: If successful, this could confirm that aztreonam-avibactam is a reliable treatment option for multidrug-resistant infections in critically ill patients.
What could go wrong: This is an observational registry, not a controlled trial, so results may be less definitive. The drug may not work for all resistant bacteria, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANTIBIOTIC RESISTANCE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Infections infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANTIBIOTIC RESISTANCE CRITICAL CARE INFECTION INFECTIOUS DISEASES

Contacts and locations

Locations

French Society of Intensive Care (SRLF)

Paris, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.